Biocon Ltd. Therapeutic and Overview Pipeline Review H2


Biocon Ltd. Treatment Pipeline Review H2 2016

PUNE, INDIA, November 14, 2016 / — The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Get Sample Report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

– The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited
– The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses Biocon Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features Biocon Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate Biocon Limited’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Biocon Limited
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Biocon Limited’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Biocon Limited Snapshot 5
Biocon Limited Overview 5
Key Facts 5
Biocon Limited – Research and Development Overview 6
Key Therapeutic Areas 6
Biocon Limited – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Biocon Limited – Pipeline Products Glance 13
Biocon Limited – Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Biocon Limited – Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Biocon Limited – Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Biocon Limited – Drug Profiles 18
adalimumab biosimilar – Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
bevacizumab biosimilar – Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
BVX-20 – Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
etanercept biosimilar – Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
filgrastim – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
insulin aspart – Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
insulin glargine – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
insulin human – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
insulin lispro – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
insulin tregopil – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
itolizumab – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30

Access Report @

Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR